MMSL 2022, 91(1):65-73 | DOI: 10.31482/mmsl.2021.046

PATHOGEN REDUCTION OF BLOOD COMPONENTSReview article

Dominik Kutáč ORCID...1,2, Miloš Bohoněk ORCID...1,3, Jan M. Horáček ORCID...2,4*
1 Oddělení hematologie a krevní transfuze, Ústřední vojenská nemocnice – Vojenská fakultní nemocnice Praha, Česká republika
2 Katedra vojenského vnitřního lékařství a vojenské hygieny, Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové, Česlá republika
3 Fakulta biomedicínského inženýrství, České vysoké učení technické v Praze, Česká republika
4 IV. interní hematologická klinika, Fakultní nemocnice Hradec Králové a Lékařská fakulta Univerzity Karlovy, Hradec Králové, Česká republika

Nově se objevující, ale i stávající a známé infekční hrozby představují stálou výzvu v oblasti zajištění bezpečnosti krve a krevní transfuze. Kromě bezpříspěvkového dárcovství a pečlivého výběru dárců krve a jejích složek, robustních postupů laboratorního screeningu představuje významnou doplňující alternativu ve zvýšení bezpečnosti transfuzních přípravků tzv. patogen redukce. Tento stručný přehledový článek shrnuje informace o principu a použití patogen redukčních technologií v transfuzním lékařství a také nejnovější výzkumy týkající se jejich možného budoucího použití.

Keywords: PRT; patogen redukce; patogen inaktivace

Emerging, as well as existing and known infectious threats represent a constant challenge in ensuring blood safety and blood transfusions. In addition to non-contributory donations and careful selection of blood donors and its components, robust laboratory screening procedures represent a significant complementary alternative in increasing the safety of transfusion products, the so-called pathogen reduction. This brief review article summarizes information on the principle and application of pathogen reduction technologies in transfusion medicine, as well as the latest research on their possible future application.

Keywords: PRT; pathogen reduction; pathogen inactivation

Received: November 17, 2021; Revised: December 7, 2021; Accepted: December 8, 2021; Prepublished online: January 17, 2022; Published: March 4, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kutáč, D., Bohoněk, M., & Horáček, J.M. (2022). PATHOGEN REDUCTION OF BLOOD COMPONENTS. MMSL, 91(1), 65-73. doi: 10.31482/mmsl.2021.046
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 2000;14:94-110. Go to original source... Go to PubMed...
    2. Ticehurst JR, Pisanic N, Forman MS, et al. Probable transmission of hepatitis E virus (HEV) via transfusion in the United States. Transfusion. 2019;59:1024-34. Go to original source... Go to PubMed...
    3. Dalton HR, Seghatchian J. Hepatitis E virus: emerging from the shadows in developed countries. Transfus Apher Sci. 2016;55:271-4. Go to original source... Go to PubMed...
    4. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. J Am Med Assoc. 2003;289:959-62. Go to original source... Go to PubMed...
    5. Burnouf T, Seghatchian J. Ebola virus convalescent blood products: where we are now and where we may need to go. Transfus Apher Sci. 2014;51:120-5. Go to original source... Go to PubMed...
    6. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang. 2013 Apr;104(3):183-99. Go to original source... Go to PubMed...
    7. Fast LD, DiLeone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion. 2011 Jul;51(7):1397-404. Go to original source... Go to PubMed...
    8. Fast LD, Dileone G, Li J, et al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006 Apr;46(4):642-8. Go to original source... Go to PubMed...
    9. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant. 2004 Jan;33(1):1-7. Go to original source... Go to PubMed...
    10. Fast LD, DiLeone G, Cardarelli G, et al. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion. 2006 Sep;46(9):1553-60. Go to original source... Go to PubMed...
    11. Goodrich RP, et al., Chapter 5: "The Antiviral and Antibacterial Properties of Riboflavin and Light: Applications to Blood Safety and Transfusion Medicine." Flavins: Photochemistry and Photobiology, vol. 6, 2006, Royal Society of Chemistry; Cambridge, United Kingdom. E Silva and AM Edwards, editors.
    12. World Health Organization Recommendations for the production, quality control and regulation of plasma for fractionation. Geneva: World Health Organization; 2005http://www.who.int/bloodproducts2005.
    13. Burnouf T, Barro L, Nebie Q, et al. Viral safety of human platelet lysate for cell therapy and regenerative medicine: moving forward, yes, but without forgetting the past. Transfus Apher Sci. 2019;58:102674. Go to original source... Go to PubMed...
    14. Bohonek M, Kutac D, Acker JP, et al. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview. Transfus Apher Sci. 2020 Apr;59(2):102754. Go to original source... Go to PubMed...
    15. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992 Feb 1;79(3):826-31. Go to original source...
    16. Prowse CV: Pathogen inactivation of blood components. Transfus Alternat Transfus Med. 2008; 10:139-146 Go to original source...
    17. Council of Europe, European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS), Symposium on Implementation of Pathogen Reduction Technologies for Blood Components September 2010 Executive Summary available at: http://www.edqm.eu/medias/fichiers/Executive_Summary_Pathogen_Reduction. pdf Accessed 5th November 2011
    18. Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep. 2003 Nov;2(6):495-502. Go to PubMed...
    19. Benjamin RJ, Braschler T, Weingand T, et al. Hemovigilance monitoring of platelet septic reactions with effective bacterial protection systems. Transfusion. 2017 Dec;57(12):2946-2957. Go to original source... Go to PubMed...
    20. Schmidt M, Hourfar MK, Sireis W, et al. Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains. Transfusion. 2015 Sep;55(9):2104-12. Go to original source... Go to PubMed...
    21. Dodd RY, Foster GA, Stramer SL. Keeping Blood Transfusion Safe from West Nile Virus: American Red Cross Experience, 2003 to 2012. Transfus Med Rev. 2015 Jul;29(3):153-61. Go to original source... Go to PubMed...
    22. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply--time to raise the bar. N Engl J Med. 2015 May 14;372(20):1882-5. Go to original source... Go to PubMed...
    23. Wollowitz S: Targeting DNA and RNA in pathogens: mode of action of amotosalen HCl. Transfus Med Hemother. 2004; 31(Suppl 1):11-16. Go to original source...
    24. Marschner S, Fast LD, Baldwin WM 3rd, et al. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion. 2010 Nov;50(11):2489-98. Go to original source... Go to PubMed...
    25. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004 Jul-Aug;80:15-21. Go to original source... Go to PubMed...
    26. Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Transfus Apher Sci. 2009 Apr;40(2):79-85. Go to original source... Go to PubMed...
    27. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion. 2010 Nov;50(11):2362-75. Go to original source... Go to PubMed...
    28. Picker SM, Tauszig ME, Gathof BS. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion. 2012 Mar;52(3):510-6. Go to original source... Go to PubMed...
    29. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion. 2008 Aug;48(8):1685-92. Go to original source... Go to PubMed...
    30. Perez-Pujol S, Tonda R, Lozano M, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion. 2005 Jun;45(6):911-9. Go to original source... Go to PubMed...
    31. Ambruso DR, Thurman G, Marschner S, Goodrich RP. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion. 2009 Dec;49(12):2631-6. Go to original source... Go to PubMed...
    32. Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion. 2010 Apr;50(4):926-31. Go to original source... Go to PubMed...
    33. Hornsey VS, Drummond O, Morrison A, et al. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion. 2009 Oct;49(10):2167-72. Go to original source... Go to PubMed...
    34. Allain JP, Mihaljevic I, Gonzalez-Fraile MI, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013 Jul;53(7):1405-15. Go to original source... Go to PubMed...
    35. Weusten J, Vermeulen M, van Drimmelen H, et al. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion. 2011 Jan;51(1):203-15. Go to original source... Go to PubMed...
    36. Donegan E, Lenes BA, Tomasulo PA, et al. Transmission of HIV-1 by component type and duration of shelf storage before transfusion. Transfusion. 1990 Nov-Dec;30(9):851-2. Go to original source... Go to PubMed...
    37. Busch MP, Operskalski EA, Mosley JW, et al. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. Transfusion Safety Study Group. J Infect Dis. 1996 Jul;174(1):26-33. Go to original source... Go to PubMed...
    38. McCullough J, Alter HJ, Ness PM. Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy. Transfusion. 2019 Mar;59(3):1132-1146. Go to original source... Go to PubMed...
    39. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev. 2009 Apr;23(2):124-33. Go to original source... Go to PubMed...
    40. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion. 2005 Aug;45(8):1335-41. Go to original source... Go to PubMed...
    41. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion. 2004 Dec;44(12):1732-40. Go to original source... Go to PubMed...
    42. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion. 2006 Oct;46(10):1778-86. Go to original source... Go to PubMed...
    43. Cancelas JA, Dumont LJ, Rugg N, et al. Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process. Transfusion. 2011 Nov;51(11):2367-76. Go to original source... Go to PubMed...
    44. Cancelas JA, Rugg N, Fletcher D, et al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion. 2011 Jul;51(7):1460-8. Go to original source... Go to PubMed...
    45. Drew VJ, Barro L, Seghatchian J, et al. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus. 2017 Oct;15(6):512-521. Go to PubMed...
    46. Allain JP, Goodrich R. Pathogen reduction of whole blood: utility and feasibility. Transfus Med. 2017 Oct;27 Suppl 5:320-326. Go to original source... Go to PubMed...
    47. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion. 2003 Oct;43(10):1481-92. Go to original source... Go to PubMed...
    48. Marschner S, Goodrich R. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. Transfus Med Hemother. 2011;38(1):8-18. Go to original source... Go to PubMed...
    49. Lin L, Conlan MG, Tessman J, et al. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 2005 Oct;45(10):1610-20. Go to original source... Go to PubMed...
    50. Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008 Apr;22(2):133-53. Go to original source... Go to PubMed...
    51. Kutac D, Bohonek M, Landova L, et al. Pathogen reduction of frozen platelets. Vox Sang. 2019;114:16.
    52. Waters L, Padula MP, Marks DC, et al. Cryopreservation of UVC pathogen-inactivated platelets. Transfusion. 2019; 59: 2093-2102. Go to original source... Go to PubMed...
    53. Meinke S, Wikman A, Gryfelt G, et al. Cryopreservation of buffy coat-derived platelet concentrates photochemically treated with amotosalen and UVA light. Transfusion. 2018; 58: 2657-2668. Go to original source... Go to PubMed...
    54. Johnson L, Cameron M, Waters L, et al. The impact of refrigerated storage of UVC pathogen inactivated platelet concentrates on in vitro platelet quality parameters. Vox Sang. 2019 Jan;114(1):47-56. Go to original source... Go to PubMed...
    55. Bohoněk M, Řezáč D, Holub M. Production and use of convalescent plasma in COVID-19 treatment, taking into account the experience in the Central Millitary Hospital Prague. Cas Lek Cesk. 2020 Summer;159(5):175-180. Go to PubMed...
    56. Kutac D, Bohoněk M, Landova L, et al. Storage of UV light and riboflavin treated RBC after cryopreservation and reconstitution in AS-3 additive solution. Vox Sang. 2020; 115:P-296.

    Return to the content